newsfilter
← Latest News
GlobeNewswire·

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,